BSTG - Biostage, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
2.2100
+0.0100 (+0.45%)
At close: 2:43PM EST
Stock chart is not supported by your current browser
Previous Close2.2000
Open2.2200
BidN/A x N/A
AskN/A x N/A
Day's Range2.2100 - 2.2200
52 Week Range0.7500 - 3.0000
Volume1,561
Avg. Volume1,612
Market Cap16.892M
Beta (5Y Monthly)1.55
PE Ratio (TTM)N/A
EPS (TTM)-1.3430
Earnings DateMar 25, 2020 - Mar 29, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Biostage Provides Update on FDA Investigational New Drug Application for its Lead Product Candidate Cellspan™ Esophageal Implant
    PR Newswire

    Biostage Provides Update on FDA Investigational New Drug Application for its Lead Product Candidate Cellspan™ Esophageal Implant

    Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants, received the anticipated formal response from the U.S. Food and Drug Administration (FDA) related to the Company's Investigational New Drug (IND) application for the Cellspan Esophageal Implant (CEI).

  • Biostage Receives Response from the FDA for Investigational New Drug Application for its Lead Product Candidate Cellspan™ Esophageal Implant
    PR Newswire

    Biostage Receives Response from the FDA for Investigational New Drug Application for its Lead Product Candidate Cellspan™ Esophageal Implant

    Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants, today announced that it was notified via email on November 27, 2019 by the U.S. Food and Drug Administration (FDA) that the Company's Investigational New Drug (IND) application for its lead product candidate, the Cellspan Esophageal Implant (CEI), has been placed on clinical hold.

  • Newsfile

    Biostage, Inc. Discusses Potential Clinical Trials for Their Next-Generation Esophageal Implants

    Phoenix, Arizona--(Newsfile Corp. - November 25, 2019) - The Stock Day Podcast welcomed Biostage, Inc. (OTCQB: BSTG) ("the Company"), a bioengineering company that is developing next-generation esophageal implants. CEO of the Company, Jim McGorry, joined Stock Day host Everett Jolly. Jolly began the interview by noting that the Company's primary product is an esophageal implant called the Cellspan Esophageal Implant, or CEI. He then asked about the Company's recent IND application with the FDA. ...

  • Biostage Reports Third Quarter 2019 Financial Results
    PR Newswire

    Biostage Reports Third Quarter 2019 Financial Results

    HOLLISTON, Mass. , Nov. 12, 2019 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a bioengineering company developing next-generation esophageal implants, today announced its financial results for the three ...

  • ­­Biostage to Host Conference Call to Discuss Third Quarter 2019 Financial Results and Business Update
    PR Newswire

    ­­Biostage to Host Conference Call to Discuss Third Quarter 2019 Financial Results and Business Update

    HOLLISTON, Mass., Nov. 6, 2019 /PRNewswire/ -- Biostage, Inc. (BSTG), a bioengineering company developing next-generation esophageal implants, announced today that it will report its financial results for the three and nine months ended September 30, 2019 in a press release that will be issued pre-market on Tuesday November 12, 2019. Biostage management also announced that it will host a conference call with a live audio webcast that same day at 9:00 AM ET to review its operational progress and financial report. The live audio webcast will be accessible on the Events page of the Investors section on the Company's website at www.biostage.com and will be archived for 60 days.

  • Biostage Submits Investigational New Drug (IND) Application for Lead Product Candidate Cellspan™ Esophageal Implant for Treatment of Esophageal Conditions
    PR Newswire

    Biostage Submits Investigational New Drug (IND) Application for Lead Product Candidate Cellspan™ Esophageal Implant for Treatment of Esophageal Conditions

    HOLLISTON, Mass., Oct. 30, 2019 /PRNewswire/ -- Biostage, Inc. (BSTG), a bioengineering company developing next-generation esophageal implants, today announced it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the Company's lead product candidate, the Cellspan Esophageal Implant (CEI). Biostage filed its IND application to address an unmet medical need where patients requiring surgical treatment of esophageal disease currently face complication rates of over 50%, multiple surgeries, and a less than optimal quality of life. Biostage's technology has the potential to not only avoid multiple complex surgeries, but also improve the patient's quality of life compared to the current standard of care.

  • Newsfile

    Biostage, Inc. Joins the Stock Day Podcast to Discuss Their Pending FDA Application

    Phoenix, Arizona--(Newsfile Corp. - September 3, 2019) - The Stock Day Podcast welcomed Jim McGorry of Biostage, Inc. (OTCQB: BSTG) ("the Company"), a biotechnology startup developing bioengineered organ implants based on its Cellspan technology that combines a proprietary biocompatible scaffold with a patient's own stem cells to create bioengineered organ implants. McGorry is the Company CEO and director, and was joined by Stock Day host Everett Jolly. Jolly began the interview by asking ...

  • Biostage Reports Second Quarter 2019 Financial Results
    PR Newswire

    Biostage Reports Second Quarter 2019 Financial Results

    -- Preparing to file first IND in September 2019 HOLLISTON, Mass. , Aug. 13, 2019 /PRNewswire/ -- Biostage, Inc.  (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company ...

  • Biostage to Host Conference Call to Discuss Second Quarter 2019 Financial Results and Business Update
    PR Newswire

    Biostage to Host Conference Call to Discuss Second Quarter 2019 Financial Results and Business Update

    HOLLISTON, Mass., Aug. 7, 2019 /PRNewswire/ -- Biostage, Inc. (BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it will report its financial results for the three and six months ended June 30, 2019 in a press release that will be issued pre-market on Tuesday August 13, 2019. Biostage management also announced that it will host a conference call with a live audio webcast that same day at 9:00 AM ET to review its operational progress and financial report. The live audio webcast will be accessible on the Events page of the Investors section on the Company's website at www.biostage.com and will be archived for 60 days.

  • Biostage Reports First Quarter 2019 Financial Results
    PR Newswire

    Biostage Reports First Quarter 2019 Financial Results

    - Preparing to file first IND in Q3 2019 HOLLISTON, Mass. , May 14, 2019 /PRNewswire/ --  Biostage, Inc.  (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing ...

  • ACCESSWIRE

    Biostage, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May, 14, 2019 / Biostage, Inc. (OTCQB: BSTG ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May, 14, 2019 at 9:00 AM Eastern Time. ...

  • Biostage to Host Conference Call to Discuss First Quarter 2019 Financial Results and Business Update
    PR Newswire

    Biostage to Host Conference Call to Discuss First Quarter 2019 Financial Results and Business Update

    HOLLISTON, Mass., May 8, 2019 /PRNewswire/ -- Biostage, Inc. (BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it will report its financial results for the three months ended March 31, 2019 in a press release that will be issued pre-market on Tuesday May 14, 2019.  Biostage management also announced that it will host a conference call with a live audio webcast that same day at 9:00 AM ET to review its operational progress and financial report. The live webcast will be accessible on the Events page of the Investors section on the Company's website at www.biostage.com, and will be archived for 60 days. Biostage is a biotechnology company developing bioengineered organ implants based on the Company's Cellframe™ technology which combines a proprietary biocompatible scaffold with a patient's own stem cells to stimulate tissue regeneration in certain organs.

  • Biostage Reports 2018 Financial Results
    PR Newswire

    Biostage Reports 2018 Financial Results

    - Pre-clinical and human compassionate use clinical evidence support IND filing mid-year 2019 HOLLISTON, Mass. , March 28, 2019 /PRNewswire/ --  Biostage, Inc.  (OTCQB: BSTG) ("Biostage" or the ...

  • Biostage to Host Conference Call to Discuss 2018 Financial Results and Business Update
    PR Newswire

    Biostage to Host Conference Call to Discuss 2018 Financial Results and Business Update

    HOLLISTON, Mass., March 21, 2019 /PRNewswire/ -- Biostage, Inc. (BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it will report its financial results for the quarter and year ended December 31, 2018 in a press release that will be issued pre-market on Thursday March 28, 2019.  Biostage management also announced that it will host a conference call with a live audio webcast that same day at 9:00 AM ET to review its operational progress and financial report. The live webcast will be accessible on the Events page of the Investors section on the Company's website at www.biostage.com, and will be archived for 60 days. Biostage is a biotechnology company developing bioengineered organ implants based on the Company's Cellframe™ technology which combines a proprietary biocompatible scaffold with a patient's own stem cells to stimulate tissue regeneration in certain organs.

  • First-In-Human Case Using Biostage's Bioengineered Esophageal Implant is Presented at Major Surgical Meeting
    PR Newswire

    First-In-Human Case Using Biostage's Bioengineered Esophageal Implant is Presented at Major Surgical Meeting

    HOLLISTON, Mass., Jan. 28, 2019 /PRNewswire/ -- Dennis Wigle, M.D., Ph.D, chair of thoracic surgery at Mayo Clinic in Rochester, Minnesota, speaking at the Society of Thoracic Surgeons Tech-Con 2019 meeting on January 26, announced for the first time the details of a single-patient case report that describes the use of new technology to repair the patient's esophagus following esophageal reconstruction associated with the removal of a tumor mass in the chest. The technology being developed by Biostage, Inc. (BSTG), the Cellspan™ Esophageal Implant product candidate (CEI), uses a synthetic tubular scaffold seeded with the patient's stem cells to repair and restore a living biologic conduit. This milestone advancement demonstrated that segmental esophageal reconstruction using a stem cell-coated implant can facilitate reconstruction, regrowth and regeneration of a gastrointestinal tissue in a human patient.